retatrutide triple agonist glp-1 gip glucagon receptor Agonism Based Therapies for Obesity retatrutide mechanism glp-1 gip glucagon

Fallon MD, Perry HM, 3rd, Bergfeld M, Droke D, Teitelbaum SL, Avioli LV

The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs

Luna, R

For cell culture applications, prepare fresh dilutions into serum-free media immediately before use, as serum albumin and transferrin in complete media can sequester the copper ion over extended incubation periods, altering the effective GHK-Cu concentration

doi: 10.3389/fnut.2023.1214734 Received 24 May 2023 Accepted 21 August 2023 Published 04 September 2023 Volume 10 - 2023 Edited by Mohammed S